Form 8-K - Current report:
SEC Accession No. 0000950170-24-022266
Filing Date
2024-02-28
Accepted
2024-02-28 17:15:06
Documents
12
Period of Report
2024-02-28
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K janx-20240228.htm   iXBRL 8-K 40461
  Complete submission text file 0000950170-24-022266.txt   164484

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT janx-20240228.xsd EX-101.SCH 31937
13 EXTRACTED XBRL INSTANCE DOCUMENT janx-20240228_htm.xml XML 4898
Mailing Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130
Business Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130 (858) 751-4493
Janux Therapeutics, Inc. (Filer) CIK: 0001817713 (see all company filings)

EIN.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40475 | Film No.: 24696857
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)